BSE filing, NSE: IOLCP. Summary written from the filing by ALFA Finder's alert engine.
IOL Chemicals and Pharmaceuticals Ltd: key numbers
- Share price
- ₹184.93
- Market cap
- ₹5,428 Cr
- Revenue (annual)
- ₹2,319 Cr
- Net profit (annual)
- ₹137.6 Cr
- P/E (TTM)
- 32.3×Sector 48.7×
- Promoter holding
- 62.28%+0.00% QoQ
- FII holding
- 7.26%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from IOL Chemicals and Pharmaceuticals Ltd
All →IOL Chemicals and Pharmaceuticals Board Meeting Date
IOL Chemicals scheduled its board meeting for 30 Oct 2026 to consider unaudited Q1/H1 results. Trading window remains closed until 2 Nov 2026.
IOL Chemicals and Pharmaceuticals Other Announcement
The company submitted its quarterly shareholding pattern for the quarter ended September 30, 2026, in compliance with SEBI regulations.
IOL Chemicals and Pharmaceuticals Other Announcement
IOL Chemicals and Pharmaceuticals Limited informed the Exchange about the dispatch of reminder letters to shareholders holding physical shares for updating their KYC details.
IOL Chemicals and Pharmaceuticals Earnings Call Transcript: Key Takeaways
IOL Chemicals announced three strategic initiatives involving INR 500 Cr investment: Ibuprofen capacity expansion (to 18,000 MTPA), a new CDMO formulations facility, and a dedicated specialty chemical tolling facility.
- Call
- Guides 20% growth
IOL Chemicals and Pharmaceuticals Capacity Expansion: ₹350 Cr Investment
IOL Chemicals and Pharmaceuticals Ltd will expand Ibuprofen capacity by 6,000 MTPA. The project, requiring a ₹350 Crore investment, is expected to be commercialized by December 2027.
- Value
- ₹350.0 Cr
- Execution
- December 2027
- manufacturing capacity
- 6000.0 MTPA
IOL Chemicals and Pharmaceuticals Capacity Expansion: ₹495 Cr Investment
IOLCP announces three capacity expansions at Barnala: 6,000 MTPA Ibuprofen unit, CDMO formulation facility, and specialty chemicals tolling plant. Total investment ₹495 Crore funded via internal accruals.
- Value
- ₹495.0 Cr
- ibuprofen manufacturing capacity
- 6000 MTPA
Other regulatory approval announcements
All →Hikal Regulatory Approval
Hikal's Bengaluru API facility received a Swissmedic GMP Certificate of Compliance. The certification supports wider access to European and other regulated markets.
Sun Pharmaceutical Industries Regulatory Approval
Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.
RNFI Services Regulatory Approval
RNFI received RBI no-objection to acquire control of Smart Payment Solutions Private Limited. Remaining tranches may proceed, but no transaction value is disclosed.
Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.
Kalyani Cast-Tech Regulatory Approval
Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.